Epidermal Growth Factor Receptor Mutation Status and Rad51 Determine the Response of Glioblastoma to Multimodality Therapy with Cetuximab, Temozolomide, and Radiation

Purpose: EGFR amplification and mutation (i.e., EGFRvIII) are found in 40% of primary GBM tumors and are believed to contribute to tumor development and therapeutic resistance. This study was designed to investigate how EGFR mutational status modulates response to multimodality treatment with cetuxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachsberger, Phyllis Rachelle, Lawrence, Richard Yaacov, Liu, Yi, Rice, Barbara, Daskalakis, Constantine, Dicker, Adam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563086/
https://www.ncbi.nlm.nih.gov/pubmed/23383403
http://dx.doi.org/10.3389/fonc.2013.00013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563086/
https://www.ncbi.nlm.nih.gov/pubmed/23383403
http://dx.doi.org/10.3389/fonc.2013.00013

Ejemplares similares